首页> 外文期刊>European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fuer Pharmazeutische Verfahrenstechnik e.V >Influence of processing parameters and formulation factors on the drug release from tablets powder-coated with Eudragit L 100-55.
【24h】

Influence of processing parameters and formulation factors on the drug release from tablets powder-coated with Eudragit L 100-55.

机译:加工参数和配方因素对Eudragit L 100-55粉末包衣片剂中药物释放的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of this study was to develop a dry powder coating process for chlorpheniramine maleate (CPM) tablets using Eudragit L 100-55 as the delayed release polymer. Powder coating, a water and organic solvent-free process, was investigated as a method to prevent the migration of an ionizable, highly water soluble model drug into the polymeric film during the coating process. Eudragit L 100-55 was pre-plasticized with triethyl citrate (TEC) using hot-melt extrusion at levels of 20%, 30%, and 40%, based on the polymer weight. The extrudate was subsequently cut into pellets and cryogenically ground into a fine powder. Talc was incorporated into the coating powder as an anti-tack agent. PEG 3350 was used as a primer for the powder coating of tablets with pre-plasticized Eudragit L 100-55. The addition of polyethylene glycol 3350 (PEG 3350) to the pre-plasticized Eudragit L 100-55 was necessary to enhance the adhesion of the coating powder to the tablet cores. PEG 3350 also improved film formation and coalescence of the polymeric particles due to its plasticization effects on the acrylic polymer. For comparison, theophylline tablets were also coated with pre-plasticized Eudragit L 100-55. Theophylline was selected as a less water soluble model drug. The powder coating process was performed in a modified laboratory scale spheronizer. The drug release rate was dependent both on TEC content and the coating level. The stability of the powder-coated CPM tablets was confirmed at 25 degrees C/60% RH over a storage time of 12 weeks.
机译:这项研究的目的是开发一种使用Eudragit L 100-55作为延迟释放聚合物的马来酸氯苯那敏(CPM)片剂的干粉包衣方法。粉末涂料是一种无水和无有机溶剂的工艺,它是一种在涂层工艺中防止可电离的高度水溶性模型药物迁移到聚合物薄膜中的方法。使用基于聚合物重量的20%,30%和40%的热熔挤出法,用柠檬酸三乙酯(TEC)对Eudragit L 100-55进行预塑化。随后将挤出物切成粒料并低温研磨成细粉。将滑石粉作为防粘剂掺入到涂料粉末中。 PEG 3350用作底漆,用于预增塑的Eudragit L 100-55的片剂粉末包衣。必须向预塑化的Eudragit L 100-55中添加聚乙二醇3350(PEG 3350),以增强包衣粉末对片剂核的粘附力。 PEG 3350由于其对丙烯酸类聚合物的增塑作用,还改善了聚合物颗粒的成膜性和聚结性。为了比较,茶碱片剂还用预塑化的Eudragit L 100-55包衣。选择茶碱作为水溶性较小的模型药物。粉末涂覆过程在改进的实验室规模的滚圆机中进行。药物释放速率取决于TEC含量和涂层水平。粉末包衣的CPM片剂的稳定性在25℃/ 60%RH下在12周的存储时间内被证实。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号